The targeted inhibition of these stem cell biomarkers is one of the promising approaches to eliminate cancer stemness.38 Ning et al. found that anti-CD133 antibody conjugated SN-38 nanoparticles could abolish the CSC population in CRC.39 Zhao et al. found that anti-CD133 monoclonal antibody (MS133) could successfully prevent tumour growth in CRC.40 Potentially, the most promising therapeutic implication of our findings is that inhibition of CD133 significantly increased the sensitivity of LoVo/ADR cells to DOX, and the tumour size and tumour weight showed similar results. This evidence concerns the gene PROM1 and colorectal carcinoma.